Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Payables (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Payables data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Payables rose 136.26% year-over-year to $5.9 million; the TTM value through Sep 2025 reached $5.9 million, up 136.26%, while the annual FY2024 figure was $2.5 million, 47.37% up from the prior year.
  • Payables reached $5.9 million in Q3 2025 per STOK's latest filing, up from $4.3 million in the prior quarter.
  • Across five years, Payables topped out at $5.9 million in Q3 2025 and bottomed at $766000.0 in Q4 2022.
  • Average Payables over 4 years is $2.9 million, with a median of $2.5 million recorded in 2024.
  • Peak YoY movement for Payables: plummeted 56.8% in 2023, then surged 153.53% in 2024.
  • A 4-year view of Payables shows it stood at $766000.0 in 2022, then soared by 121.28% to $1.7 million in 2023, then soared by 47.37% to $2.5 million in 2024, then soared by 135.03% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $5.9 million in Q3 2025, $4.3 million in Q2 2025, and $2.2 million in Q1 2025.